tailieunhanh - Pharmaceutical Substances Syntheses, Patents, Applications - Part 219

Pharmaceutical Substances Syntheses, Patents, Applications - Part 219. Reference containing a collection of 2267 active pharmaceutical ingredients, including those launched recently. Listed alphabetically according to their INNs and established a link between INNs, structure, synthesis and production processes, patent and literature situation, medical use, and trade names. For pharmacists and researchers. | Voglibose V 2181 By extraction from Ammi visnaga L. Umbelliferae and chromatographic purification. Reference s US2816 118 S. B. Penick Co. prior. . US 2 980 699 S. B. Penick Co. prior. . Formulation s cps. 70 mg Trade Name s D Carduben Madaus wfm F Vibeline Roger Bellon J Visnamine Chinoin wfm Voglibose ATC A10 Use antidiabetic antiobesity a-glucosidase inhibitor RN 83480-29-9 MF C10H21NO7 MW CN 3 4-dideoxy-4- 2-hydroxy-l- hydroxymethyl ethyl amino -2-C- hydroxymethyl -D-epi-inositol N0HCO3 ethyl acetate 1. Br2 HjO 2. NoBH . HjO 1 ------------------------ 2. sodium borohydride 0 II O NH OH Ba OH 2 H20 a ------- _-------- OH HO PS vNH2 HO St OH OH valiolomine 11 1 3-dihydroxy-acetone NaBHjCN DMF 2N HCI ------------- sodium cyono-borohydride Reference s EP 56 194 Takeda Chem. appl. J-prior. . Hori s. et al. J. Med. Chem. JMCMAR 29 1038 1986 . EP 260 121 Takeda Chem. appl. J-prior. . EP240 175 Takeda Chem. appl. J-prior. . 2182 V Voglibose uncoated tablets with improved resistance EP 610 854 Takeda Chem. appl. J-prior. . composition for promoting calcium absorption EP 364 696 Takeda Chem. appl. J-prior. . EP 197 661 Takeda Chem. appl. 1986 J-prior. 11 3 1985 . EP 194 794 Takeda Chem. appl WO-prior. 8 . combination for obesity treatment WO 8 605 094 Takeda Chem. appl. WO-prior. . EP 638 317 Hoffmann-La Roche appl. CH-prior. . Formulation s tabl. mg mg Trade Name s J Basen Takeda Glustat Takeda Warfarin w 2183 Warfarin ATC B01AA03 Use anticoagulant RN 81-81-2 MF C19H16O4 MW EINECS 201-377-6 LD50 165 mg kg M . 3 mg kg M . 1600 pg kg R . 3 mg kg dog . CN 4-hydroxy-3- 3-oxo-l-phenylbutyl -2H-l -benzopyran-2-one sodium salt RN 129-06-6 MF C19H15NaO4 MW EINECS 204-929-4 LD5i

• Sinh học
• 2267 hoạt chất dược phẩm
• Sách nghiên cứu dược
• hoạt chất dược phẩm
• tổng hợp quá trình sản xuất
• sáng chế thuốc